Showing results (51-60 of 108) with videos related to
Sort By:
Pageof 11
Bulletin Du Cancer|January 31, 2026
[French recommendations for clinical practice, Nice-Saint-Paul de Vence 2024-2025: Management of high-grade ovarian epithelial cancer]Frédéric Selle, Manuel Rodrigues, Benoît You, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2010
Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancerAndreas du Bois, Jørn Herrstedt, Anne-Claire Hardy-Bessard, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2009
Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trialMarc Spielmann, Henri Roché, Thierry Delozier, et al.Gynecologic Oncology|November 18, 2018
Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trialClémence Romeo, Florence Joly, Isabelle Ray-Coquard, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2019
Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA TrialUrsula A Matulonis, Lydia Walder, Trine J Nøttrup, et al.European Journal of Cancer (Oxford, England : 1990)|October 22, 2019
UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroupVéronique D'Hondt, Jean-Luc Canon, Lise Roca, et al.Breast Cancer (Tokyo, Japan)|January 5, 2023
CHEOPS trial: a GINECO group randomized phase II assessing addition of a non-steroidal aromatase inhibitor to oral vinorelbine in pre-treated metastatic breast cancer patientsCaroline Bailleux, Antoine Arnaud, Jean-Sébastien Frenel, et al.Cancer Cell|January 20, 2023
Base editing screens map mutations affecting interferon-γ signaling in cancerMatthew A Coelho, Sarah Cooper, Magdalena E Strauss, et al.Nature|June 1, 2022
The longitudinal dynamics and natural history of clonal haematopoiesisMargarete A Fabre, José Guilherme de Almeida, Edoardo Fiorillo, et al.Gynecologic Oncology|December 25, 2021
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trialPhilipp Harter, Marie Ange Mouret-Reynier, Sandro Pignata, et al.Pageof 11